Clinical Trials
59 results for Kidney/Renal Cancer
1-50 of 59 Next
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Intervention: Device: CyberKnife
- Study ID: NCT01890590
Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders
- Condition: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Synd
- Intervention: Procedure: Haploidentical Bone Marrow/Kidney
- Study ID: NCT01758042
An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours
- Condition: Carcinoma, Neuroendocrine
- Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
- Study ID: NCT01876771
Phase Ib Trial Of Pembrolizumab And Nintedanib
- Condition: Patients With Any Advanced Solid Tumors.
- Intervention: Drug: Nintedanib, Drug: Pembrolizumab
- Study ID: NCT02856425
Kidney Cancer DNA Registry
- Condition: Renal Cancer
- Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
- Study ID: NCT02087852
Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
- Condition: Renal Tumor
- Intervention: Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03747133
Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies
- Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
- Study ID: NCT03682289
FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)
- Condition: Mucositis
- Study ID: NCT03581773
An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse
- Condition: Renal Cell Carcinoma
- Intervention: Drug: Durvalumab, Drug: Tremelimumab
- Study ID: NCT03288532
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma
- Condition: Kidney Cancer
- Study ID: NCT03414827
REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study
- Condition: Advanced or Metastatic Renal Cell Carcinoma
- Study ID: NCT04106349
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
- Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
- Study ID: NCT04071223
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers
- Condition: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal C
- Study ID: NCT05544929
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
- Condition: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Study ID: NCT05327686
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Study ID: NCT06053658
Phase 2, Open-label, Two Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib or Cabozantinib Plus Nivolumab on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)
- Condition: RCC, Renal Cell Carcinoma
- Study ID: NCT05931393
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney
- Condition: Renal Carcinoma
- Study ID: NCT06290427
A Prospective, Open-label, Single-center Study of CD70-Specific PET/CT Imaging for Non-invasive Diagnosis of Renal Cell Carcinoma
- Condition: RCC, Renal Cell Cancer
- Study ID: NCT06769893
A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma (RCC)
- Study ID: NCT07172386
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
- Condition: Renal Cell Carcinoma (RCC)
- Study ID: NCT05410509
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
- Condition: Carcinoma, Renal Cell, Diagnostic Imaging, Pathology, Deep Learning
- Study ID: NCT07166445
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as a Single Agent in Patients Wit
- Condition: Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic Cancer, Renal Cell Carcinoma (RCC)
- Study ID: NCT07172802
An Open-label, Investigator-initiated, Single Arm, Exploratory Phase 2 Trial Evaluating the Feasibility and Efficiency of PET/CT Directed Free of Therapy Used for Metastatic and Advanced Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
- Study ID: NCT07175480
Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial, From 2025 to 2027
- Condition: RCC, Renal Cell Cancer
- Study ID: NCT07190638
Characterizing the Tumor-draining Lymph Nodes and Other Immune Sites in Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma (RCC)
- Study ID: NCT07038733
Cabozantinib and Nivolumab Among Older Patients With Renal-cell Carcinoma, a Prospective Cohort With Geriatric, Pharmacologic and Patient-reported-outcome Evaluation
- Condition: Kidney Cancer, Renal Cell Cancer
- Study ID: NCT06934057
Indocyanine Green (ICG) Guided Tumor Resection
- Condition: Neoplastic Disease, Solid Tumor
- Study ID: NCT04084067
Clinical Study of CD70-Targeted Chimeric Antigen Receptor T Lymphocytes (CAR-T) in Advanced CD70-Positive Malignant Solid Tumors
- Condition: Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic Carcinoma
- Study ID: NCT07181720
Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
- Condition: Renal Carcinoma, Nephrectomy / Methods, Pain Management
- Study ID: NCT07092566
Standard Flank Approach vs Supine Approach for Robot-assisted Partial Nephrectomy: a Randomized Clinical Trial
- Condition: Kidney Neoplasm
- Study ID: NCT07234409
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® (US-sourced Keytruda®) in Multiple Resected Solid Tumors
- Condition: Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Study ID: NCT07160335
Patient-partnered Research: a Key to Investigating Fear of Cancer Recurrence in Patients With Surgically Treated Kidney Cancer (PP-RECURK)
- Condition: Fear of Cancer Recurrence, Renal Cell Carcinoma (Kidney Cancer)
- Study ID: NCT07234656
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer - FRAGECO - Multicenter, Controlled, Randomized Study
- Condition: Bladder (Urothelial, Transitional Cell) Cancer, Kidney (Renal Cell) Cancer
- Study ID: NCT07073703
Observational Study on the Abscopal Efect by Ultra-hypofractionated Radiation Therapyin Combination With Immune Checkpoint Inhibiters for Metastatic Renal Cell Carcinoma
- Condition: Renal Cell Cancer Metastatic
- Study ID: NCT07240610
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
- Condition: Renal Cell Carcinoma
- Study ID: NCT07301827
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
- Condition: Renal Cell Carcinoma
- Study ID: NCT07227402
A Prospective Clinical Study on the Predictive Value of CEUS and Super-resolution Imaging Technology for Renal Function Outcome in Patients After Partial or Radical Nephrectomy
- Condition: Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury
- Study ID: NCT07294859
An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
- Condition: Advanced Renal Cell Carcinoma
- Study ID: NCT07239596
A Phase 1b/2 Study Evaluating the Safety and Preliminary Efficacy of OM-RCA-01, an Anti-FGFR1 Monoclonal Antibody, in Patients With Metastatic Cancers Expressing FGFR1.
- Condition: Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Breast Cancer Metastatic, Head & Neck Cancer
- Study ID: NCT07292168
A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Condition: Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous
- Study ID: NCT07189871
The Impact of Cold Ischemia on Recovery From Ischemia After Robot-assisted Partial Nephrectomy: A Randomized Controlled Clinical Study
- Condition: Renal Cell Carcinoma, Renal Function Abnormal
- Study ID: NCT07326280
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)
- Condition: Advanced Renal Cell Carcinoma (RCC)
- Study ID: NCT07293351
A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)
- Condition: Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Study ID: NCT07128680
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA
- Condition: Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metasta
- Study ID: NCT07227415
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Condition: Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Study ID: NCT07188896
Phase II Single-arm Clinical Study of the Efficacy and Safety of Pucotenlimab in Combination With Vorolanib Neoadjuvant Therapy for Patients With High-risk Renal Carcinoma Indicating Partial Nephrectomy
- Condition: Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
- Study ID: NCT07386158
The Efficacy and Safety of Iparomlimab and Tuvonralimab (QL1706) Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cancer With Partial Nephrectomy Indications But High Surgical Risk：A Single Arm, Phase II Clinical Study
- Condition: Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Study ID: NCT07389629
Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy
- Condition: Kidney Cancer
- Study ID: NCT06882486
Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
- Condition: Renal Tumors
- Study ID: NCT06868927
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
- Condition: Phase 1b, HC-7366, SHARK, Kidney Cancer
- Study ID: NCT07401875